Short answer
Rapport Therapeutics, Inc. (RAPP) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results and business highlights announced for quarter ended September 30, 2026.
Rapport Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results and business highlights announced for quarter ended September 30, 2026
- Full financial figures and operating updates available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Phase 2 bipolar mania success: 3.1-point placebo-adjusted YMRS improvement, supporting RAP-219 expansion beyond epilepsy
- Safety favorable, but TEAE discontinuations 3.2% versus 0.8% for placebo
- Two bipolar mania Phase 3 trials targeted for 2H 2027, pending FDA End-of-Phase 2 meeting in 1Q 2027
- Phase 3 FOS trials enrolling, with PGTCS Phase 3 planned for 1H 2027
- Financing and ATM proceeds approximately $420.7 million, supporting runway through end-2029 despite Q3 net loss $40.2 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Rapport Therapeutics, Inc. 8-K filings
Get the next RAPP 8-K as it lands
Follow RAPP for push alerts, or ask the research agent what this filing means.